Background: As per the guidelines of the World Health Organization, HIV-infected children who do not achieve viral suppression while under antiretroviral therapy (ART) receive enhanced adherence counseling (EAC) with follow-up viral load (VL). A persisting unsuppressed VL after EAC triggers switch to a second-line regimen. We describe the care cascade of children with unsuppressed VL while taking ART.
INTRODUCTION
Globally, an estimated 2.6 million children under the age of 15 years are living with HIV, of which 88% are residing in Sub-Saharan Africa. 1 During the past years, the number of children receiving antiretroviral therapy (ART) in Sub-Saharan Africa increased 2 and is expected to further grow in the years to come. 3 The growing number of children on first-line ART will, over time, result in more children and adolescents who fail first-line regimens and requiring secondline ART. 4, 5 Because immunological and clinical monitoring is unreliable in detecting virologic failure in children, 6 the World Health Organization (WHO) issued in 2013 the recommendation to use viral load (VL) as the preferred monitoring strategy. 7 The burden of unsuppressed VL is generally higher among children and adolescents than among adults. 8 A recently published meta-analysis of virologic outcomes in children in resource-limited settings included 72 studies, of which 58 were from Sub-Saharan Africa, and reports a 12-month virologic success rate of 72.7% [95% confidence interval (CI): 62.6% to 82.8%] among children who initiated first-line ART after 2010, 9 as compared to 84.3% (80.4%-87.9%) in a meta-analysis on adult patients taking ART. 10 Despite obviously higher rates of unsuppressed viremia in children taking ART, only few studies have addressed the problem of pediatric treatment failure, and data on outcomes for children in Sub-Saharan Africa with detectable viremia continue to be scarce. 8 Children with unsuppressed VL and their caregivers enter a complex and difficult road to viral resuppression. As per WHO guidelines, children and caregivers should receive enhanced adherence counseling (EAC) and a follow-up VL 3-6 months thereafter. If the follow-up VL remains unsuppressed despite good adherence, switch to second-line ART is indicated. Once on second-line, viral resuppression should be achieved within 6 months. 11 This entire process initiated by a first unsuppressed VL is long and delicate requiring a lot of commitment from each side, the children, caregivers, and health care providers.
To the best of our knowledge, there is currently no study reporting on the care cascade of children with unsuppressed VL on first-line ART in Sub-Saharan Africa. In this registered prospective cohort study, we describe the care cascade from a first unsuppressed VL to viral resuppression in pediatric patients observed in 10 nurse-led clinics in rural Lesotho.
METHODS

Study Design and Setting
The prospective observational study on comorbidities and virologic outcome among patients on ART in rural Lesotho was conducted in 10 rural facilities in 2 districts in Lesotho, Southern Africa (www.clinicaltrials.gov; NCT02126696). All facilities (2 hospitals and 8 health centers) provide nurse-based HIV care for approximately 6000 patients on ART, including about 400 children. The study assessed viral suppression among patients on ART in Lesotho, who did not have access to VL testing before the study. Results from a cross-sectional first-time VL measurement among children have been published previously. 12 In this study, we report the 18-month follow-up for those children who had unsuppressed VL at the initial time point.
Study Population and Procedures
Children aged ,16 years and on first-line ART for $6 months attending their regular ART visit during May or June 2014 at 1 of the 10 study clinics were included. Detailed inclusion criteria and recruitment procedures in the CART-1 study have been published earlier. 12 Figure 1 displays study flow and time points for the assessment. A first crosssectional VL determination had been conducted in May/June 2014. Unsuppressed viral replication was defined as VL $80 copies per milliliter. All children with an initial unsuppressed VL were included in the prospective cohort study. Management followed current WHO and Lesotho guidelines: children and their caregivers were informed about the unsuppressed VL result and received EAC with second VL 3 months after EAC (October 2014). EAC addressed the participant as well as his/her caregiver, including at least 1 of 2 options: one-to-one adherence counseling with a nurse/lay counselor or focus group discussions among children with unsuppressed VL and their caregivers. In cases of sustained unsuppressed viremia at the follow-up VL measurement, children were considered ART-failing, and a switch to second-line was recommended to the ART-nurse in charge of the clinical care for that child. In patients with a suppressed second VL, continuation of firstline ART was recommended. 11, 13 The second-line regimens available in Lesotho at the time of conduction of the study consisted of ritonavir-boosted lopinavir plus lamivudine and one of the nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir, zidovudine, or abacavir. Responsibility for the medical management of children enrolled in the study remained with the health care providers at the clinics at all times. The study team only provided information on the VL results and recommended clinical management as per Lesotho and WHO guidelines.
Clinical and virologic outcomes were assessed again 18 months (December 2015) after the initial determination of an unsuppressed VL. For this, study nurses consulted the clinical records of each enrolled child. Children who were still retained in care were contacted for a blood draw for follow-up VL in December 2015. All children not retained in care or where clinical records were doubtful were individually traced to assess their outcome. Tracing was performed using phone, and those patients who could not be reached were personally traced by a village health worker who visited the child's and/or caregiver's home.
Data Collection and Statistical Analysis
At enrollment, trained lay counselors interviewed caregivers using a structured questionnaire. Subsequently, an ART-nurse conducted the clinical assessment and filled in the medical history from the clinical record, and the child underwent phlebotomy for laboratory assessment. Collected blood samples were transported to the nationally accredited laboratories in 2 hospitals, namely Seboche Hospital and Paray Hospital, for routine laboratory examinations (full blood count, liver function tests, creatinine, and CD4 cell count). For VL determination, EDTA-blood was centrifuged within 8 hours, plasma stored at 280 degrees, and sent frozen to a reference laboratory in Switzerland. VL determination was performed with a sensitive in-house protocol with a quantification limit at below 80 copies per milliliter, targeting the viral LTR 14 and validated against the commercial diagnostic protocol COBAS TaqMan HIV-1 test, v2.0.
The clinical outcome was categorized as "retained in care with viral suppression" (VL ,80 copies/mL), "retained in care without viral suppression," "retained in care without documentation of VL," "dead" if the caregiver or the village chief confirmed the death, "transferred out" if a written confirmation of the child being in care at another facility was available, or "LTFU" if the child's status of care could not be ascertained.
The VL analysis for the December 2015 samples was performed on a newly installed and accredited qPCR platform in Butha-Buthe Laboratory (COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0). For quality assurance, 20% of samples were analyzed in parallel in Butha-Buthe and a reference laboratory in Switzerland. A 100% congruence for suppressed versus unsuppressed was found using the cutoff of 80 copies per milliliter. Genotypic resistance testing for unsuppressed samples was conducted in Switzerland using NucliSENS easyMag extraction of viral RNA from plasma. Genotyping results (Sanger sequencing) were classified according to the HIV Drug Resistance Database of Stanford University (http://hivdb.stanford.edu).
Statistical analysis was descriptive, following the logic of the care cascade children enter once unsuppressed VL is diagnosed. Because of the small sample size, Fisher exact test was used to compare subgroups.
Ethical Considerations
The main study protocol, entitled Chronic noncommunicable and selected communicable comorbidities, virologic failure and resistance among patients on antiretroviral therapy in rural Lesotho, has received ethical clearance from the National Ethics Committee of the Ministry of Health of Lesotho (protocol number: REF 01-2014) and has been judged as conforming to the ICH-GCP-standards by the Ethikkommission Nordwest-und Zentralschweiz (EKNZ) in Switzerland (ID 2014-029). Before enrollment, children provided verbal assent and the children's caregivers provided written consent for their child to participate in the study.
RESULTS
Of 191 children with first-time VL data, 53 (27.7%) had a VL $80 copies per milliliter in May/June 2014 and were enrolled in the prospective cohort. Table 1 displays the baseline characteristics of the enrolled children. Figure 2 shows the care cascade after a first determination of an unsuppressed VL. Of the 53 children with an elevated VL in May/June 2014, 10 (18.9%) were retained in care with viral resuppression in December 2015, 26 (49.1%) were retained in care with continuous, unsuppressed VL, and the remaining were either LTFU, dead, or had no documented VL (Fig. 2) . Table 2 groups children per result of second VL in October 2014. Among 36 children who continued having unsuppressed VL after EAC, 24 (66.7%) were switched to second-line ART as recommended by national and international guidelines using ritonavir-boosted lopinavir plus lamivudine plus an additional NRTI (19 zidovudine, 3 tenofovir, and 2 abacavir). The other 12 (33.3%) were not switched despite sustained viremia at VL test after EAC. Among the 24 switched patients, 9 (38%) were retained in care and virally suppressed by December 2015, 8 (33%) continued to have unsuppressed VL, and the remaining had no follow-up VL test. Among the 12 children not switched despite unsuppressed follow-up VL after EAC, none was retained in care with suppressed VL by December 2015. Being switched to second-line was significantly associated with being retained in care and virally suppressed at the end of the study (Table 2 , 38% versus 0%, P = 0.016).
Genotypic resistance testing was successful in 7 of 8 children with unsuppressed VL after switch to second-line ART. Only 1 child had a minor protease-inhibitor resistance mutation (T74S); all others had no indication of resistance against lopinavir. Table 3 lists detailed clinical information on the 8 children without viral resuppression after switch to second-line ART. 
DISCUSSION
This prospective cohort study, conducted in 10 rural health facilities in Lesotho, assessed the care cascade and virologic outcomes for children who presented with unsuppressed viremia while taking first-line ART. At 18 months of follow-up after a first unsuppressed VL, only 19% of children were alive and in care with documented VL suppression. Several children were lost at every step of the care cascade. Two steps were, however, particularly problematic: First, against the National and WHO guidelines, one-third of the children were not switched to second-line ART despite ongoing viral replication after EAC. Second, even among those switched to second-line, less than half were still retained in care with suppressed VL at 18 months of follow-up. These figures from rural nurse-led clinics may provide a serious but realistic picture of the outcomes for children who do not achieve viral suppression in similar settings.
To the best of our knowledge, this is the first publication reporting on the full care cascade from first unsuppressed VL to EAC, to follow-up VL after EAC, switch to second-line, and outcome after switch to second-line in children in Sub-Saharan Africa. There are, however, several studies on clinical or virologic outcomes of children who were switched to second-line ART after failing first-line therapy in Africa: A retrospective cohort study in Ethiopia among 53 children switched to second-line ART found that 86% were retained in care 2 years after switch. 15 This study did not report on virologic outcomes. A study in an urban hospital in Durban, South Africa, found 80% of all children switched to a protease inhibitor-based second-line regimen to achieve viral suppression after 6 months. 16 Musiime et al 17 report from a Ugandan cohort that 85% of their patients, switched and retained in care with documented follow-up VL, achieved viral resuppression (,400 copies/mL) after 48 weeks. In a second study from Uganda, 80% achieved viral resupression. 18 Schoeffelen et al 19 reported that 20 of 39 children achieved VL ,50 copies per milliliter 12 months after switch to second-line in a rural clinic in South Africa.
It remains puzzling why outcomes of children in our study were so poor. Because our study looks at the entire care cascade, it also included children who should have been 20 report a reluctance to switch to second-line in adult patients among health care providers in a clinic in Johannesburg. A possible reason may be that nurses who followed the children at the clinic were not familiar with the drugs lopinavir/ritonavir and thus, hesitated to change the regimen. In the same setting, we have been able to show earlier that introduction of a new first-line regimen took significantly longer in nurse-led health centers as compared to hospitals. 21 However, even if switched to second-line, only 38% of children switched were retained in care with documented viral suppression and 33% remained in care with continued high VLs despite second-line ART. This may partly be due to nonoptimal second-line regimens because most continued unchanged NRTIs (zidovudine/lamivudine) and only changed from nevirapine or efavirenz to ritonavirboosted lopinavir. As shown in Table 3 , among the 8 children with treatment failure on second-line, 7 had NRTI mutations and 4 had accumulated thymidine analog mutations. In adults, switch to protease inhibitor containing second-line ART may be successful even in case of major drug resistance mutations against the NRTIs of the second-line regimen. 22, 23 However, larger trial data are lacking for children. One small retrospective study in children reports that a majority could maintain viral suppression despite major drug resistance mutations against their ART regimen. 24 A recent review concluded that there is no evidence comparing efficacy of the WHO-recommended second-line regimens with alternative regimens in children. 25 As shown in Table 3 , none of the 8 children with ongoing treatment failure on second-line had developed resistance against lopinavir, indicating that ongoing poor adherence may be a major driver for continuing unsuppressed VL. A recent study in Uganda reports similar findings. 18 In a larger cohort of children failing second-line therapy in Asia, 6 of 53 failing children carried HIV with protease inhibitor mutations. 26 In contrast to these studies, Rossouw et al 27 report that 49% of children failing a protease inhibitor-containing regimen carried major resistance mutations against protease inhibitors. This study, however, included children with advanced clinical disease and a long treatment history of protease inhibitor-containing ART. Our study has several limitations. First, similar to other studies on treatment failure in children, the sample size is small. Second, all facilities in the study receive support from SolidarMed, a Swiss-based not-for-profit organization. Outcomes may thus be poorer in those facilities where no similar external support is available. Third, we do not have information on potential exposure of children to prevention of mother-to-child transmission, which may have caused resistance to first-line ART, ie, non-NRTIs. 28 Finally, the study's generalizability must be limited to children already taking first-line ART and attending care during the recruitment period in 2014.
The proportion achieving viral suppression through ART is generally lower among children as compared to adults. 8, 29 Our study provides evidence that even if treatment failure in children is recognized through VL monitoring, management is rarely successful in real-life settings. Less than 1 of 5 children with diagnosed unsuppressed VL was active in care with resuppressed VL at 18-month follow-up. In the same setting among adults with diagnosed unsuppressed VL in 2014, 41% were retained in care with resuppressed VL by December 2015. 30 In summary, in this study conducted in rural nurse-led clinics in rural Lesotho, poor outcomes of children with unsuppressed VL were due to weaknesses at every step of the care cascade, including loss to follow-up before switch to second-line, failure to switch to second-line at health care provider level, and continued unsuppressed VL despite switch to a protease inhibitor-based second-line regimen. Future studies are encouraged to not limit reporting to outcomes in children switched to second-line ART but consider all cases of unsuppressed viremia at every step, to provide a more realistic picture of the care cascade in children who do not achieve viral suppression while taking first-line ART.
